Jun 2026 (Q2 FY26) — Aug 6, 2026
LifeStance Q2 FY26 — Exceeds Guidance with Strong Revenue Growth and Margin Expansion
Read the full callLifeStance (LFST) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
LifeStance earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 435 | +26.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 7.0 | +7.9 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 23.6 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$11.77 +0.26% · +$0.03
Performance +133.5% 1Y
1Y: $5.04 on 17 Oct 2025 → $11.77. High $13.38 (14 Sept 2026), low $4.81 (5 Nov 2025).
- Previous close
- $11.74
- 52-week range
- $4.81 – $13.38
- One year
- +128.10%
Overview
- Symbol
- LFST
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Dec 2025 (Q4 FY25) — Feb 25, 2026
LifeStance Health Q4 FY25 — Record Performance and Accelerated Margin Expansion
Read the full callEvery analysed call
LifeStance earnings calls (LFST)
Financials
What the filings say
Net profit, year on year: +723% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 313 | 325 | 333 | 345 | 364 | 382 | 403 | 435 |
| Operating profit | 0 | 1 | 2 | -3 | 7 | 18 | 22 | 31 |
| Operating margin | 0.0% | 0.3% | 0.5% | −0.8% | 2.0% | 4.7% | 5.5% | 7.0% |
| Other income | -5 | -10 | -3 | -3 | -3 | -3 | -3 | -3 |
| Interest | 5 | 9 | 3 | 3 | 3 | 3 | 2 | 3 |
| Profit before tax | -5 | -9 | -1 | -6 | 5 | 15 | 20 | 27 |
| Tax rate | −10.7% | 19.9% | 148.2% | 36.2% | 76.4% | 23.3% | 27.9% | 14.0% |
| Net profit | 1 | -7 | 1 | -4 | 1 | 12 | 14 | 24 |
| Line item | Dec 2019 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Equity capital | — | 4 | 4 | 4 | 4 | 4 |
| Reserves | — | -357 | -573 | -761 | -818 | -809 |
| Total liabilities | — | 382 | 655 | 681 | 672 | 683 |
| Fixed assets | — | 152 | 194 | 188 | 166 | 162 |
| Total assets | — | 1,927 | 2,174 | 2,110 | 2,118 | 2,204 |
| Line item | Dec 2019 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Cash from operations | 17 | 9 | 53 | -17 | 107 | 146 |
| Cash from investing | -73 | -194 | -139 | -60 | -22 | -36 |
| Cash from financing | 48 | 314 | 47 | 47 | -10 | -16 |
| Net cash flow | -8 | 129 | -39 | -30 | 76 | 94 |
| Capital expenditure | -14 | -94 | -79 | -41 | -22 | -36 |
| Free cash flow | 3 | -85 | -26 | -57 | 86 | 110 |
LFST operating KPIs by quarter
| KPI | Dec 2025 Q4 FY25 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| Employees Clinicians | 8,040We grew our net clinicians by 44 in the fourth quarter and 657 for the full year, bringing our total clinician base to 8,040, representing growth of 9% year-over-year.Source: earnings call transcript | 8,542This was achieved while at the same time adding 193 clinicians in the second quarter, bringing our total clinician base to 8,542, representing growth of 11%.Source: earnings call transcript | +6.2% |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Insider filings
96 filings between Nov 10, 2025 and Sep 22, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$847.23M
37 sales by 9 insiders
59% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 26
- Award — granted as compensation
- 28
- Tax withheld — shares kept back by the company to cover tax
Also filed: 4 gifts, 1 other.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| TPG GP A, LLC | — | $742.97M | Sep 11, 2026 |
| BLACK DARREN M. | — | $77.56M | May 12, 2026 |
| Bessler Robert | — | $16.39M | Jun 26, 2026 |
| Burdick Kenneth A | — | $5.75M | Aug 11, 2026 |
| Shuey Eric | — | $1.95M | May 12, 2026 |
| Paunovich Vukasin | — | $1.02M | Sep 2, 2026 |
| Miller Lisa K | — | $887.9K | Aug 10, 2026 |
| DeLuca Teresa | — | $345.1K | Aug 14, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 22, 2026 | Bourdon David Chief Executive Officer | Gift | 150,000 | $0 |
| Sep 22, 2026 | Bourdon David Chief Executive Officer | Gift | 150,000 | $0 |
| Sep 22, 2026 | Bourdon David Chief Executive Officer | Gift | 150,000 | $0 |
| Sep 22, 2026 | Bourdon David Chief Executive Officer | Gift | 150,000 | $0 |
| Sep 11, 2026 | TPG GP A, LLC 10% owner | Sale | 18,409,705 | $226.26M |
| Sep 2, 2026 | Bourdon David Chief Executive Officer | Other | 150,000 | $0 |
| Sep 2, 2026 | Paunovich Vukasin Chief Technology Officer | Sale | 42,067 | $541.4K |
| Aug 24, 2026 | Varanakis Ann Chief People Officer | Tax withheld | 8,156 | $99.2K |
| Aug 14, 2026 | DeLuca Teresa Director | Sale | 7,500 | $95.1K |
| Aug 13, 2026 | DeLuca Teresa Director | Sale | 20,441 | $250.0K |
| Aug 11, 2026 | Burdick Kenneth A Director | Sale | 500,000 | $5.75M |
| Aug 10, 2026 | Miller Lisa K Chief Operating Officer | Sale 10b5-1 plan | 47,912 | $519.8K |
| Aug 10, 2026 | Paunovich Vukasin Chief Technology Officer | Sale 10b5-1 plan | 44,394 | $481.7K |
| Aug 10, 2026 | TPG GP A, LLC 10% owner | Sale | 13,643,207 | $144.89M |
| Jul 6, 2026 | Burdick Kenneth A Director | Award | 45,495 | $0 |
| Jul 2, 2026 | Palmer Eric P Director | Award | 17,746 | $0 |
| Jul 2, 2026 | Personette Sarah Director | Award | 17,746 | $0 |
| Jul 2, 2026 | Goltermann Lori Director | Award | 35,492 | $0 |
| Jul 2, 2026 | DeLuca Teresa Director | Award | 17,746 | $0 |
| Jul 2, 2026 | Bessler Robert Director | Award | 17,746 | $0 |
| Jul 2, 2026 | Justice Thurman Director | Award | 35,492 | $0 |
| Jun 26, 2026 | Bessler Robert Director | Sale 10b5-1 plan | 447,169 | $4.53M |
| Jun 26, 2026 | Bessler Robert Director | Sale 10b5-1 plan | 447,168 | $4.53M |
| Jun 11, 2026 | Paunovich Vukasin Chief Technology Officer | Tax withheld | 17,456 | $150.3K |
| May 12, 2026 | TPG GP A, LLC 10% owner | Sale | 28,281,943 | $226.82M |
| May 12, 2026 | Bessler Robert Director | Sale | 287,517 | $2.31M |
| May 12, 2026 | Bessler Robert Director | Sale | 287,517 | $2.31M |
| May 12, 2026 | BLACK DARREN M. Director | Sale | 5,899,661 | $47.32M |
| May 12, 2026 | Shuey Eric Director | Sale | 243,362 | $1.95M |
| May 7, 2026 | Bessler Robert Director | Sale 10b5-1 plan | 37,500 | $320.6K |
| May 7, 2026 | Bessler Robert Director | Sale 10b5-1 plan | 37,500 | $320.6K |
| Apr 24, 2026 | Bessler Robert Director | Sale 10b5-1 plan | 31,074 | $219.1K |
| Apr 24, 2026 | Bessler Robert Director | Sale 10b5-1 plan | 31,073 | $219.1K |
| Apr 23, 2026 | Bessler Robert Director | Sale 10b5-1 plan | 3,876 | $27.1K |
| Apr 23, 2026 | Bessler Robert Director | Sale 10b5-1 plan | 3,876 | $27.1K |
| Apr 21, 2026 | Bessler Robert Director | Sale 10b5-1 plan | 2,550 | $17.9K |
| Apr 21, 2026 | Bessler Robert Director | Sale 10b5-1 plan | 2,551 | $17.9K |
| Apr 1, 2026 | Pardo Ryan See Remarks | Tax withheld | 9,376 | $59.7K |
| Mar 24, 2026 | McGroarty Ryan See Remarks | Tax withheld | 24,255 | $156.4K |
| Mar 17, 2026 | McGroarty Ryan See Remarks | Tax withheld | 47,594 | $327.9K |
| Mar 9, 2026 | Miller Lisa K Chief Operating Officer | Tax withheld | 14,766 | $102.0K |
| Mar 9, 2026 | Varanakis Ann Chief People Officer | Tax withheld | 25,024 | $172.9K |
| Mar 9, 2026 | Varanakis Ann Chief People Officer | Award | 26,836 | $0 |
| Mar 9, 2026 | Varanakis Ann Chief People Officer | Tax withheld | 8,707 | $60.2K |
| Mar 9, 2026 | Pardo Ryan See Remarks | Tax withheld | 38,479 | $265.9K |
| Mar 9, 2026 | Pardo Ryan See Remarks | Award | 105,711 | $0 |
| Mar 9, 2026 | Pardo Ryan See Remarks | Tax withheld | 15,841 | $109.5K |
| Mar 9, 2026 | Pardo Ryan See Remarks | Award | 40,254 | $0 |
| Mar 9, 2026 | Pardo Ryan See Remarks | Tax withheld | 12,280 | $84.9K |
| Mar 9, 2026 | McGroarty Ryan See Remarks | Tax withheld | 25,644 | $177.2K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for LifeStance Health Group, Inc.
Free account. Everything above stays public.
Write why you follow LifeStance Health Group, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading